Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Successful DFA settlement reachedCompany with cash and cash equivalents of approximately USD20MDr Fred Guerard, CEO, Tom Reilly...
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52O...
Leerink Partners analyst Marc Goodman downgrades Opthea (NASDAQ:OPT) from Outperform to Market Perform and lowers the price ...
HC Wainwright & Co. analyst Matthew Caufield downgrades Opthea (NASDAQ:OPT) from Buy to Neutral and lowers the price tar...
Jefferies analyst Kelly Shi downgrades Opthea (NASDAQ:OPT) from Buy to Underperform and announces $1 price target.
Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces...
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52Opthea considering impact of...
Baseline angiographic lesion characteristics predictive of clinical responsePublished in peer-reviewed journal Ophthalmic Surge...
